AstraZeneca plans to submit the positive data Breztri Aerosphere in asthma for to regulatory authorities for review.

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

Europe meeting, experts discussed the challenges and strategies of small and mid-sized biopharma companies surrounding ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...

Among those consuming UPFs in high-income countries, intake varies significantly across age and socioeconomic status.

The US FDA has confirmed proteinuria as an acceptable primary endpoint in Dimerix ‘s Phase III ACTION3 trial of DMX-200 for ...

The FDA approved AstraZeneca's Truqap in November 2023 for the treatment of advanced HR-positive breast cancer.

The Imfinzi regimen reduced risk of death by 25%, with overall survival at two years at 82% compared to 75% in the control ...